Fotivda exclusive distribution in East European markets

On May 17 Angelini Pharma signed a deal with EUSA Pharma to be the exclusive distributor for Fotivda (Tivozanib), a product indicated for first line treatment of adult patients with advanced renal cell carcinoma (RCC). The deal concerns seven different Eastern European countries: Bulgaria, Croatia, Czech Republic, Hungary, Romania, Slovenia and Slovakia.

The deal with EUSA Pharma will improve and consolidate the Angelini oncology and supportive care portfolio in EEC markets where Angelini Pharma has already established a solid presence even through partnerships with other important companies such as Helsinn, Incyte and Ethypharm. With the launch of Fotivda, Angelini will be able to offer physicians an additional therapeutic solution for a very serious disease.